Intelligent Bio Solutions Sees Revenue Growth and Improved Margins in Q3
TL;DR
INBS reported a 20% revenue increase in Q3 2025 driven by cartridge sales, strengthening its recurring revenue model.
INBS delivers rapid, non-invasive testing solutions through its Intelligent Fingerprinting Drug Screening System, revolutionizing portable testing.
INBS's technology improves workplace safety by screening for drug use, benefiting employers in safety-critical industries and promoting a healthier work environment.
INBS secured its sixth U.S. patent and expanded internationally, demonstrating innovation and growth in the medical technology industry.
Found this article helpful?
Share it with your network and spread the knowledge!
Intelligent Bio Solutions (Nasdaq: INBS) demonstrated financial progress in its fiscal third quarter of 2025, reporting a 20% sequential revenue increase to $728,867. The medical technology company's performance was primarily driven by robust cartridge sales, which now represent 58% of total revenue and are strengthening its recurring revenue model.
The company's gross profit surged 91% year-over-year to $341,368, while simultaneously reducing its net loss by $434,141 to $2.54 million. This financial improvement suggests the company is making strategic strides in operational efficiency and market penetration.
INBS expanded its market presence by adding 35 new accounts in the quarter, bringing its active customer base to over 450. The company continues to pursue international growth through strategic partnerships and multilingual system upgrades, indicating a commitment to global market expansion.
The company's technological innovation remains a key focus, with the recent securing of its sixth U.S. patent and ongoing regulatory efforts across key global markets. Its Intelligent Fingerprinting Drug Screening System, which enables rapid drug screening through fingerprint sweat analysis, potentially offers a transformative solution for workplace testing in industries such as construction, manufacturing, transport, and logistics.
The quarter's results suggest Intelligent Bio Solutions is making meaningful progress in establishing its non-invasive testing technology as a viable and potentially disruptive solution in medical diagnostics and workplace screening.
Curated from InvestorBrandNetwork (IBN)
